Holder evidence
8
SEC ownership of Anbio Biotechnology
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001982708.
Lead holder
GEODE CAPITAL MANAGEMENT, LLC
13D/G signal
—
Latest evidence
31 Mar 2026
- CIK
- 0001982708
- Symbol
- NNNN on Nasdaq
- Location
- Frankfurt Am Main, Germany
- SEC evidence mix
- 13F
- Lead holder
- GEODE CAPITAL MANAGEMENT, LLC
- Latest evidence date
- 31 Mar 2026
Issuer identity
Ownership snapshot
Ownership snapshot
Top shareholders of Anbio Biotechnology (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
GEODE CAPITAL MANAGEMENT,...
13D/G signal
—
Evidence rows
8
Latest as of
31 Mar 2026
13F
Highest disclosed value: $661,851
Rank 1 holder
GEODE CAPITAL MANAGEMENT, LLC
13F
- Ownership
- —
- Position
- $661.9K
Rank 2 holder
BNP PARIBAS FINANCIAL MARKETS
13F
- Ownership
- —
- Position
- $267.2K
Rank 3 holder
MORGAN STANLEY
13F
- Ownership
- —
- Position
- $188.5K
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
class O/S missing
|
$661,851
25,763 shares
|
— | 31 Mar 2026 |
| BNP PARIBAS FINANCIAL MARKETS |
13F
Company
|
—
class O/S missing
|
$267,176
10,400 shares
|
— | 31 Mar 2026 |
| MORGAN STANLEY |
13F
Company
|
—
class O/S missing
|
$188,513
7,338 shares
|
— | 31 Mar 2026 |
| UBS Group AG |
13F
Company
|
—
class O/S missing
|
$162,849
6,339 shares
|
— | 31 Mar 2026 |
| EverSource Wealth Advisors, LLC |
13F
Company
|
—
class O/S missing
|
$6,834
266 shares
|
— | 31 Mar 2026 |
| WELLS FARGO & COMPANY/MN |
13F
Company
|
—
class O/S missing
|
$2,569
100 shares
|
— | 31 Mar 2026 |
| Bare Financial Services, Inc |
13F
Company
|
—
class O/S missing
|
$385
15 shares
|
— | 31 Mar 2026 |
| Blue Trust, Inc. |
13F
Company
|
—
class O/S missing
|
$128
5 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 01 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-5 of 5 reporting-owner rows connected to Anbio Biotechnology. Open a relationship link for the CIK-to-CIK filing trail.
Rows
5
Lead holder
Cany Xu
Net 12M change
$0
Latest report
18 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Cany Xu | Director | Mixed | 18 Mar 2026 | |||
| Chris Tian | Cbo | Mixed | 18 Mar 2026 | |||
| Michael Lau | Ceo | Mixed | 18 Mar 2026 | |||
| Nancy Hartzler | Director | Mixed | 18 Mar 2026 | |||
| Suki Song | Cfo | Mixed | 18 Mar 2026 |
Recent insider transactions for Anbio Biotechnology
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* indicates a reported price that failed the local validity check.